Botox® vs Dysport®: Popular FDA-Approved Botulinum Toxin Comparison

✦ Provider Reference

Botox Cosmetic® and Dysport® are two of the most widely used botulinum toxin type A products in aesthetic medicine. Both are FDA-approved for the temporary improvement of glabellar lines and are commonly used off-label for additional facial areas by experienced injectors.

Although several other botulinum toxin products are now available—including Xeomin®, Jeuveau®, Daxxify®, and Letybo®—Botox and Dysport remain the two brands most frequently compared by clinicians and patients. In practice, treatment outcomes between the two products are very similar when appropriate dosing and injection technique are used, though differences in unit dosing, formulation, and diffusion characteristics are often discussed.

Please note: All brand names are registered trademarks of their respective manufacturers. There is currently no FDA-approved “generic” botulinum toxin type A product.

Read More:  A comparison of all six FDA approved toxins.

Key Facts About Botox® vs Dysport®

  • Both Botox Cosmetic® and Dysport® are botulinum toxin type A neuromodulators that work by blocking acetylcholine release at the neuromuscular junction, temporarily relaxing targeted facial muscles.
  • When appropriate dosing and injection technique are used, Botox and Dysport produce very similar cosmetic outcomes for common aesthetic treatments such as glabellar frown lines.
  • The two products differ primarily in dosing units and formulation characteristics, which means treatment doses are not interchangeable on a one-to-one basis.
  • Dysport® is often associated with a slightly faster onset of visible effect, while Botox Cosmetic® remains the most widely recognized and historically established botulinum toxin brand in aesthetic medicine.
  • For most aesthetic providers, patient results depend far more on anatomy knowledge, dosing strategy, and injection technique than on whether Botox or Dysport is selected.

 

Dysport dosing units are not equivalent to Botox units. In most aesthetic applications, approximately 2.5–3 Dysport units correspond to 1 Botox unit, although exact dosing varies by injector preference and treatment area.

Botox® vs Dysport® Comparison

CategoryBotox Cosmetic®Dysport®
FDA Approval Year20022009
ManufacturerAllergan / AbbVieGalderma
Active ToxinOnabotulinumtoxinAAbobotulinumtoxinA
Accessory ProteinsPresentPresent
Typical Onset3–5 days2–4 days (often reported faster onset)
Typical Duration3–4 months3–4 months
Conversion Ratio (Dysport : Botox)1:1~2.5–3:1 (units are not interchangeable)
Diffusion CharacteristicsMore localized spreadSlightly greater diffusion (may benefit larger treatment areas)
FDA Approved Aesthetic UsesGlabellar lines, crow’s feet, forehead lines, platysma bandsGlabellar lines
StorageRefrigeratedRefrigerated
Immunogenicity RiskVery lowVery low
Approximate Cost per Equivalent Treatment$$$$$–$$$ (often lower cost per treatment depending on conversion)
Typical Glabellar Dose20 units50–60 units

Botox Cosmetic® Overview

Botox Cosmetic® (onabotulinumtoxinA), manufactured by AbbVie/Allergan, is the most established botulinum toxin product used in aesthetic medicine. Botulinum toxin was first approved by the U.S. Food and Drug Administration (FDA) in 1989 for treatment of facial muscle spasms and other neurologic conditions. As clinicians began using the medication off-label to soften dynamic facial wrinkles during the 1990s, Botox Cosmetic® became the first botulinum toxin type A product to receive FDA approval specifically for aesthetic use.

Initial approval for glabellar frown lines occurred in 2002, followed by approvals for lateral canthal lines (crow’s feet) in 2013, forehead lines in 2017, and platysma bands of the neck in 2024. These approvals made Botox Cosmetic® the first neuromodulator with four separate FDA-approved aesthetic treatment areas.¹ ²

Like other botulinum toxin type A products, Botox works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening targeted facial muscles and reducing the appearance of dynamic wrinkles. Clinical onset typically occurs within three to five days, with maximal effect at approximately two weeks and a typical duration of three to four months for most aesthetic indications.¹

Because of its long clinical history and broad brand recognition, Botox Cosmetic® remains the most widely recognized neuromodulator brand worldwide and is often used colloquially as a generic term for cosmetic toxin injections. More than two decades of widespread aesthetic use and over 100 million distributed vials have contributed to its dominant market position.³ Market analyses suggest Botox products continue to hold roughly 60 percent of the U.S. aesthetic toxin market.⁴

Demand for neuromodulator procedures has expanded substantially over the past two decades as minimally invasive cosmetic treatments have become more widely accepted. Millions of injections are performed annually, and the global botulinum toxin market is expected to continue growing as patient demand for non-surgical facial rejuvenation increases.⁵ ⁶ For many aesthetic practices, the strong public familiarity with the Botox brand can make it easier to introduce neuromodulator treatments compared with newer toxin products.

AbbVie also supports Botox Cosmetic® with the Alle℠ loyalty and rewards program, which allows patients to accumulate points for aesthetic treatments and redeem them toward future procedures. The platform can help practices encourage repeat visits and maintain patient engagement with both the brand and their injecting provider.

References

  1. U.S. Food and Drug Administration. BOTOX Cosmetic® (onabotulinumtoxinA) Prescribing Information.
  2. Carruthers A. Treatment of crow’s feet lines and forehead lines with onabotulinumtoxinA. Dermatologic Surgery.
  3. AbbVie. BOTOX Cosmetic® brand information and global usage data.
  4. Botox® market share and industry competition overview.
  5. Aesthetic neurotoxin market size and growth analysis.
  6. Global botulinum toxin market growth projections.

 

Because Botox Cosmetic® established the early market for aesthetic neuromodulators, newer toxin products are often compared against it as a reference standard. Dysport®, approved in 2009, is the product most frequently compared with Botox in clinical practice.

Dysport® Overview

Dysport® (abobotulinumtoxinA), manufactured by Ipsen and distributed in the United States by Galderma, was the second botulinum toxin type A product approved by the U.S. Food and Drug Administration (FDA) for aesthetic use. Dysport received FDA approval in 2009 for the temporary improvement of moderate-to-severe glabellar lines in adult patients.¹ As the first major competitor to Botox Cosmetic®, Dysport entered the aesthetic market with a similar mechanism of action but with several practical differences in formulation and dosing units.

Like other botulinum toxin type A neuromodulators, Dysport works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening the facial muscles responsible for dynamic wrinkles. Clinical onset is often reported within two to four days for many patients, and some studies have suggested Dysport may demonstrate a slightly faster onset compared with onabotulinumtoxinA when equivalent clinical dosing is used.² Overall duration of effect remains broadly similar to other neuromodulators, typically lasting about three to four months for most aesthetic indications.

One commonly discussed distinction between Dysport and Botox Cosmetic® involves dosing units. Dysport units are not interchangeable with those of other botulinum toxin products, and clinical equivalence is often estimated at approximately 2.5–3 units of Dysport for every 1 unit of Botox.¹ Because of this difference in potency units, Dysport treatments generally involve a larger numerical unit dose even though the clinical outcomes are comparable. This difference can sometimes create confusion for new injectors and patients when comparing toxin dosing between brands.

Since its introduction, Dysport has become one of the most widely used botulinum toxin products globally and remains an important competitor in the neuromodulator market. The product is often associated with claims of faster onset and slightly broader diffusion characteristics, which some practitioners believe may allow smoother results in larger treatment areas such as the forehead. However, when appropriate dosing and injection technique are used, clinical studies generally demonstrate similar safety and efficacy profiles among currently approved botulinum toxin type A products.³ Over time, newer toxin entrants have gained market share, and Dysport is estimated to account for roughly 10–15 percent of aesthetic toxin use in the United States.

Galderma supports Dysport with educational programs and promotional initiatives aimed at aesthetic providers. Unlike Botox Cosmetic®, however, Dysport does not currently have a consumer loyalty platform with the scale or recognition of the Alle℠ program. As a result, while Dysport remains widely used among experienced injectors, patient awareness of the brand is often lower than that of Botox, which continues to dominate consumer recognition in many markets.

References

  1. U.S. Food and Drug Administration. Dysport® (abobotulinumtoxinA) Prescribing Information.
  2. Kane MA et al. A randomized, double-blind study comparing the onset of action of abobotulinumtoxinA and onabotulinumtoxinA for the treatment of glabellar lines. Dermatologic Surgery.
  3. Hexsel D, et al. Botulinum toxin type A products: clinical comparison and therapeutic equivalence. Dermatologic Therapy.

Frequently Asked Questions: Botox® vs Dysport®

Is Dysport® stronger than Botox®?

Dysport® is not stronger than Botox®. The two products use different potency units, so dosing is not interchangeable on a one-to-one basis. In most aesthetic treatments, approximately 2.5 to 3 units of Dysport® correspond to 1 unit of Botox®. When appropriate dosing is used, both products produce very similar clinical results.

Does Dysport® work faster than Botox®?

Some clinical studies suggest Dysport® may demonstrate a slightly faster onset of action, with visible results sometimes appearing within two to four days. Botox® typically begins working within three to five days for many patients. However, both products generally reach their maximal effect within about two weeks.

Does Dysport® last longer than Botox®?

For most aesthetic treatments, Botox® and Dysport® have similar duration of effect. Clinical results typically last about three to four months, although individual patient response, dosing, and treatment area can influence how long results remain visible.

Why does Dysport® use more units than Botox®?

Dysport® units are measured differently from Botox® units and cannot be directly compared. Because of this difference in potency units, Dysport® treatments typically involve a higher numerical dose. Clinicians often estimate that approximately 2.5–3 units of Dysport® provide a similar effect to 1 unit of Botox®.

Which is better: Botox® or Dysport®?

Neither product is universally better. Botox® has the longest clinical history and strongest brand recognition, while Dysport® is sometimes preferred by clinicians for certain treatment areas due to its dosing characteristics and diffusion profile. When used with proper technique, both neuromodulators produce safe and effective cosmetic outcomes.

Are Botox® and Dysport® interchangeable?

Although both products are botulinum toxin type A neuromodulators, their dosing units are not interchangeable. Treatment doses must be adjusted when switching between products to maintain equivalent clinical results.